Key result
Clinical, laboratory, and genetic factors were evaluated using a machine learning model to predict aspirin resistance and recurrent ischemic stroke in 296 patients, without reporting specific rates.
Why the study?
The study aimed to determine the incidence of laboratory aspirin resistance and assess associations of genetic, clinical, and laboratory parameters using machine learning to predict recurrent ischemic stroke in non-cardioembolic stroke patients.
Can a machine learning model using clinical, laboratory, and genetic markers predict laboratory aspirin resistance and recurrent ischemic stroke in patients with non-cardioembolic ischemic stroke?
Observational (n=296)
No
Can a machine learning model using clinical, laboratory, and genetic markers predict laboratory aspirin resistance and recurrent ischemic stroke in patients with non-cardioembolic ischemic stroke?
A machine learning model incorporating clinical, laboratory, and genetic factors may help identify patients at risk for aspirin resistance and recurrent ischemic stroke to guide differentiated prevention strategies.
Answers are grounded in this paper and cite their sources.
ML model may stratify aspirin resistance and recurrent stroke risk; hypothesis-generating, requires prospective validation before any clinical use.
The aim of the study was to determine the incidence of laboratory aspirin resistance; and to study the associations of genetic markers and clinical and laboratory parameters (including parameters of the platelet hemostasis) in patients with non-cardioembolic ischemic stroke using machine learning methods to assess the prognosis of recurrent ischemic strokes. Clinical and laboratory data (including induced platelet aggregation) were analyzed from 296 patients with ischemic stroke who were treated in the stroke center of City Clinical Hospital No. 1 named after. N.I. Pirogov. The frequencies of polymorphic variants of the ITGB3, GPIba, TBXA2R, ITGA2, PLA2G7, HMOX1, PTGS1, PTGS2, ADRA2A, ABCB1, PEAR1 genes and intergenic region 9p21.3) in patients with non-cardioembolic ischemic stroke, which were identified using hydrogel biochip technology, were determined. Using the developed machine learning model, additional clinical and genetic factors influencing the development of laboratory aspirin resistance and recurrent ischemic stroke were studied. In the future, the identified factors can be used for differentiated prevention of recurrent ischemic strokes.
No takes yet. Share an insight, caveat, or question.
Anastasia et al. (2024) conducted an observational in Non-cardioembolic ischemic stroke (n=296). Clinical, laboratory, and genetic factors was evaluated on Laboratory aspirin resistance and recurrent ischemic stroke. Clinical, laboratory, and genetic factors were evaluated using a machine learning model to predict aspirin resistance and recurrent ischemic stroke in 296 patients, without reporting specific rates.
Synapse has enriched 10 related papers. Consider them for comparative context: